| 000 | 01790 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515071515.0 | ||
| 264 | 0 | _c20070726 | |
| 008 | 200707s 0 0 eng d | ||
| 022 | _a0008-5472 | ||
| 024 | 7 |
_a10.1158/0008-5472.CAN-06-3996 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Chang-Shi | |
| 245 | 0 | 0 |
_aHistone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. _h[electronic resource] |
| 260 |
_bCancer research _cJun 2007 |
||
| 300 |
_a5318-27 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Retracted Publication | ||
| 650 | 0 | 4 | _aAcetylation |
| 650 | 0 | 4 |
_aAntigens, Nuclear _xmetabolism |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aDNA Breaks, Double-Stranded |
| 650 | 0 | 4 |
_aDNA Repair _xdrug effects |
| 650 | 0 | 4 |
_aDNA, Neoplasm _xdrug effects |
| 650 | 0 | 4 |
_aDNA-Binding Proteins _xmetabolism |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHistone Deacetylase Inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKu Autoantigen |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 700 | 1 | _aWang, Yu-Chieh | |
| 700 | 1 | _aYang, Hsiao-Ching | |
| 700 | 1 | _aHuang, Po-Hsien | |
| 700 | 1 | _aKulp, Samuel K | |
| 700 | 1 | _aYang, Chih-Cheng | |
| 700 | 1 | _aLu, Yen-Shen | |
| 700 | 1 | _aMatsuyama, Shigemi | |
| 700 | 1 | _aChen, Ching-Yu | |
| 700 | 1 | _aChen, Ching-Shih | |
| 773 | 0 |
_tCancer research _gvol. 67 _gno. 11 _gp. 5318-27 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/0008-5472.CAN-06-3996 _zAvailable from publisher's website |
| 999 |
_c17085036 _d17085036 |
||